Tin tức & Cập nhật

A significant association exists between metabolic syndrome (MetS) and an increased risk of excessive scarring, highlighting the potential of MetS management in preventing scarring, according to a study.

In the phase III SUNRISE trial, tezepelumab significantly reduces daily maintenance oral corticosteroid (OCS) dose while maintaining asthma control in adults with severe OCS-dependent asthma, despite early study termination and the smaller-than-planned sample size.